Home›Companies›Biotech & Pharma›Kylix Bio

Kylix Bio, Inc.

Develops gene therapies for people with rare neuromuscular diseases.

Updated Nov 16, 2026·Latest SEC filing Jan 26, 2026·Suggest an edit

About Kylix Bio

Kylix Bio is a private company based in Dover, Delaware, incorporated in 2025 in Delaware. It has reported $850,000 raised in one offering on Form D since January 2026. Its chief executive is Catherine Illingworth.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jan 15, 2026Jan 26, 2026$850,000of $12.0M target5$170KOptionsRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Kylix Bio's Form D filed Jan 26, 2026.

HW
Hunter Watts
Director
Catherine Illingworth
Catherine Illingworth
Chief Executive Officer & Founder, director

Sources

  1. SECKylix Bio, Inc. filing history
  2. CompanyOur Story
  3. InvestorPraxis portfolio: Kylix Bio